Medical management update: Multiple myeloma

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 103, Issue 5, 2007, Pages 599-609

  Stoopler, Eric T ^a   Vogl, Dan T ^b   Stadtmauer, Edward A ^b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; THALIDOMIDE;

BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DENTAL CARE; DRUG ANTAGONISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JAW DISEASE; JAW TUMOR; METASTASIS; MULTIPLE MYELOMA; ORAL BLEEDING; PATHOLOGY; REVIEW;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BORONIC ACIDS; DENTAL CARE FOR CHRONICALLY ILL; DIPHOSPHONATES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JAW DISEASES; JAW NEOPLASMS; MULTIPLE MYELOMA; ORAL HEMORRHAGE; OSTEONECROSIS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; THALIDOMIDE;

EID: 34247332275     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2006.10.026     Document Type: Review

References (76)

1. American Cancer Society. Cancer Facts and Figures 2006 (2006), American Cancer Society, Atlanta (GA). http://www.cancer.org/docroot/STT/stt_0.asp Available at: http://www.cancer.org/docroot/STT/stt_0.asp. Accessed September 15, 2006
2. Munshi N.C., Tricot G., and Barlogie B. Plasma cell neoplams. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer principles and practice of oncology. 6th ed. (2001), Lippincott Williams & Wilkins, Philadelphia (PA) 2465-2499
3. Sirohi B., and Powles R. Multiple myeloma. Lancet 363 (2004) 875-887
4. Kuehl W.M., and Bergsagel P.L. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 1 (2005) 346-352
5. Dimopoulos M.A., Kyle R.A., Anagnostopoulos A., and Treon S.P. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 23 (2005) 1564-1577
6. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121 (2003) 749-757
7. Kyle R.A. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 64 (1978) 814-826
8. Kyle R.A., Therneau T.M., Rajkumar S.V., Larson D.R., Plevak M.F., and Melton L.J. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 79 (2004) 859-866
9. Kyle R.A., Therneau T.M., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.F., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346 (2002) 564-569
10. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting features, response to treatment and survival. Cancer 36 (1975) 842-854
11. Greipp P.R., Miguel J.S., Durie B.G., Crowley J.J., Barlogie B., Blade J., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
12. Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 16 (1998) 3832-3842
13. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 488-493
14. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al., Myeloma Aredia Study Group. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16 (1998) 593-602
15. Musto P., Falcone A., Sanpaolo G., Bodenizza C., Cascavilla N., Melillo L., et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 44 (2003) 1545-1548
16. Attal M., Harousseau J.L., Leyvraz S., Doyen C., Hulin C., Benboubker L., et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02). [abstract]. Blood 104 (2004) 535
17. Lacy M.Q., Dispenzieri A., Gertz M.A., Greipp P.R., Gollbach K.L., Hayman S.R., et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81 (2006) 1047-1053
18. Alexanian R., Dimopoulos M.A., Delasalle K., and Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 80 (1992) 887-890
19. Rajkumar S.V., Blood E., Vesole D., Ronseca R., and Greipp P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
20. Cavo M., Zamagni E., Tosi P., Tacchetti P., Cellini C., Cangini D., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
21. Dimopoulos M.A., Pouli A., Zervas K., Grigoraki V., Symeonidis A., Repoussis P., et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 14 (2003) 1039-1044
22. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
23. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
24. Barlogie B., Shaughnessy J., Tricot G., Jacobson J., Zangari M., Anaissie E., et al. Treatment of multiple myeloma. Blood 103 (2004) 20-32
25. Samuels B.L., and Bitran J.D. High-dose intravenous melphalan: a review. J Clin Oncol 13 (1995) 1786-1799
26. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98 (2001) 492-494
27. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
28. Dimopoulos M.A., Spencer A., Attal M., Prince M., Harousseau J.L., Dmoszynska A., et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). [abstract]. Blood 106 (2005) 6
29. Osterborg A., Boogaerts M.A., Cimino R., Essers U., Holowiecki J., Juliusson G., et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study. Blood 87 (1996) 2675-2682
30. Musto P. The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma. Leuk Lymphoma 29 (1998) 283-291
31. Alexanian R., Barlogie B., and Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 150 (1990) 1693-1695
32. Blade J., Fernandez-Llama P., Bosch F., Montoliu J., Lens X.M., Montoto S., et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158 (1998) 1889-1893
33. Clark W.F., Stewart A.K., Rock G.A., Sternbach M., Sutton D.M., Barrett B.J., et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143 (2005) 777-784
34. Callender N.S., and Roodman G.D. Myeloma bone disease. Semin Hematol 38 (2001) 276-285
35. Dudeney S., Leiberman I.H., Reinhardt M.-K., and Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 20 (2002) 2382-2387
36. Morgan G.J., Krishnan B., Jenner M., and Davies F.E. Advances in oral therapy for multiple myeloma. Lancet Oncol 7 (2006) 316-325
37. Crawley C., Lalancette M., Szydlo R., Gilleece M., Peggs K., Mackinnon S., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
38. Seoane J., Aguirre-Urizar J.M., Esparaza-Gomez G., Suarez-Cunqueiro M., Campos-Trapero J., and Pomareda M. The spectrum of plasma cell neoplasia in oral pathology. Med Oral 8 (2003) 269-280
39. Ozdemir R., Kayiran O., Oruc M., Karaadlan O., Kocer U., and Ogun D. Plasmacytoma of the hard palate. J Craniofac Surg 15 (2005) 164-169
40. Obuekwe O.N., Nwizu N.N., Ojo M.A., and Ugbodaga P.I. Extramedullary presentation of multiple myeloma in the parotid gland as first evidence of the disease: a review with case report. Nigerian Postgrad Med J 12 (2005) 45-48
41. Ziegler C.M., Flechtenmacher C., and Muhling J. Tender preauricular swelling. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93 (2002) 516-520
42. Mozaffari E., Mupparapu M., and Otis L. Undiagnosed multiple myeloma causing extensive dental bleeding: report of a case and review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 (2002) 448-453
43. Sirois D.A., Cohen S.G., and Greenberg M.S. Maxillofacial plasmacytoma resulting in intraoral hemorrhage in a patient with multiple myeloma. Spec Care Dentist 11 (1991) 158-161
44. Baykul T., Aydin U., and O Carroll M.K. Unusual combination of presenting features in multiple myeloma. Dentomaxillofac Radiol 33 (2004) 413-419
45. Anacak Y., Kamer S., Donmez A., and Haydaroglu A. Destruction of molar roots by metastasis of multiple myeloma. Br J Oral Maxillofac Surg 40 (2002) 515
46. Ariyaratnam S., Sweet C., and Duxbury J. Low grade multiple myeloma that presented as a labial swelling-a case report. Br Dent J 199 (2005) 433-435
47. Owotade F., Ugboko V., Ajike S., Salawu L., Amusa Y., and Omole M. Head and neck manifestations of myeloma in Nigerians. Int J Oral Maxillofac Surg 34 (2005) 761-765
48. Angtuaco E.J.C., Fassas A.B.T., Walker R., Sethi R., and Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 231 (2004) 11-23
49. Lalla R.V., and Peterson D.E. Oral mucositis. Dent Clin N Am 49 (2005) 167-184
50. Treister N.S., Woo S.B., O'Holleran E.W., Lehrmann L.E., Parsons S.K., and Guinan E.C. Oral chronic graft-verus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 721-731
51. Radfar L., and Somerman M. Glucocorticoids. In: Ciancio S.G. (Ed). ADA/PDR guide to dental therapeutics. 4th ed. (2006), ADA Publishing, Chicago 131-160
52. Migliorati C.A., Casiglia J., Epstein J., Jacobsen P.L., Siegel M.A., and Woo S.B. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc 136 (2005) 1658-1668
53. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 (2006) 508-514
54. Badros A., Weikel D., Salama A., Goloubeva O., Schneider A., and Rapoport A. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
55. Bamias A., Kastritis E., Bamia C., Molopoulos L.A., Malekopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphopsphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
56. Delibasi T., Altundag K., and Kanlioglu Y. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors. J Oral Maxillofac Surg 64 (2006) 995-996
57. Markiewicz M.R., Margarone J.E., Campbell J.H., and Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 136 (2005) 1669-1674
58. Melo M.D., and Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136 (2005) 1675-1681
59. Bayner-Garner I.B., and Smoller B.R. AL amyloidosis is not present as an incidental finding in cutaneous biopsies of patients with multiple myeloma. Clin Exp Dermatol 27 (2002) 240-242
60. Desikan K.R., Dhodapkar M.V., Hough A., Waldron T., Jagannath S., Siegel D., et al. Incidence and impact of light chain associated (AL) amyloidosis of the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 27 (1997) 315-319
61. Kyle R.A. Multiple myeloma: review of 869 cases. Mayo Clin Proc 50 (1975) 29-40
62. Stoopler E.T., Sollecito T.P., and Chen S.Y. Amyloid deposition in the oral cavity: a retrospective study and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 674-680
63. Rankin K.V., Jones D.L., and Redding S.W. Oral health care in cancer therapy. A guide for health care professionals. 2nd Edition. (2003) Monograph; Academy of General Dentistry Foundation.
64. American Academy of Pediatric Dentistry Clinical Affairs Committee. Guideline on dental management of pediatric patients receiving chemotherapy, hematopoietic cell transplantation, and/or radiation. Pediatr Dent 2005- 2006; 27:170-175.
65. In: Little J.W., Falace D.A., Miller C.S., and Rhodus N.L. (Eds). Dental management of the medically compromised patient. 6th ed. (2002), Mosby, St Louis p. DM 48-9
66. DeRossi S.S., Garfunkel A., and Greenberg M.S. Hematological diseases. In: Greenberg M.S., and Glick M. (Eds). Burket's oral medicine. 10th ed. (2003), BC Decker, Hamilton, ON, Canada 429-453
67. Pinto H.A. Leukemia, lymphoma, and multiple myeloma. In: Fishman M.C., Hoffman A.R., Klausner R.D., and Thaler M.S. (Eds). Medicine. 5th ed. (2004), Lippincott Williams & Wilkins, Baltimore (MD) 395-412
68. Firriolo F. Drug therapy in chronic renal disease. In: Hupp J., Williams T., and Firriolo F. (Eds). Dental clinical advisor (2006), Mosby, St Louis 487-488
69. Derossi S.S., and Raghavendra S. Anemia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 131-141
70. Napolitano L.M. Perioperative anemia. Surg Clin N Am 85 (2005) 1215-1227
71. Goodnough L.T., Shander A., Spivak J.L., Waters J.H., Friedman A.J., Carson J.L., et al. Detection, evaluation, and management of anemia in the elective surgical patient. Anesth Analg 101 (2005) 1858-1861
72. Pogrel M.A., and McDonald A. The use of erythropoietin in a patient having major oral and maxillofacial surgery and refusing blood transfusion. J Oral Maxillofac Surg 53 (1995) 943-945
73. Miller C.S., Little J.W., and Falace D.A. Supplemental corticosteroids for dental patients with adrenal insufficiency: reconsideration of the problem. J Am Dent Assoc 132 (2001) 1570-1579
74. Fatahzadeh M. Multiple myeloma. In: Hupp J., Williams T., and Firriolo F. (Eds). Dental clinical advisor (2006), Mosby, St Louis 139-140
75. In: Ciancio S.G. (Ed). ADA/PDR guide to dental therapeutics. 4th ed. (2006), ADA Publishing, Chicago 957-959
76. Ruggiero S., Gralow J., Marx R.E., Hoff A.O., Schubert M.M., Huryn J.M., et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2 (2006) 7-14